Risk of Changes in Pharmaceutical Regulations, Healthcare Insurance Systems and Drug Pricing
First written in FY2016. 6 of 7 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2018: 20 of 64 companies on the "Worse" side.
47 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「The company's business plan is based on existing legal regulations, the healthcare insurance system, and trends in drug pricing based on these regulations and systems. However, the products under development are expected to require a considerable period before they can actually be launched, and there is no guarantee that these regulations, systems or pricing trends will remain unchanged during that period.」
The company continues to highlight risks from changes in pharmaceutical regulations, healthcare insurance systems and drug pricing. - FY2023RestatedAnnual report
「However, the products under development are expected to require a considerable period before they can actually be launched, and there is no guarantee that these regulations, systems or pricing trends will remain unchanged during that period.」
Continues to disclose the risks of changes in pharmaceutical regulations, the healthcare insurance system and drug pricing. - FY2022RestatedAnnual report
「However, the products under development are expected to require a considerable period before they can actually be launched, and there is no guarantee that these regulations, systems or pricing trends will remain unchanged during that period.」
Continues to disclose the risks of changes in pharmaceutical regulations, the healthcare insurance system and drug pricing. - FY2021RestatedAnnual report
「However, the products under development are expected to require a considerable period before they can actually be launched, and there is no guarantee that these regulations, systems or pricing trends will remain unchanged during that period.」
Continues to indicate the risks of changes in pharmaceutical regulations, the healthcare insurance system and drug prices. - FY2020RestatedAnnual report
「The company's business plan is based on existing legal regulations, the healthcare insurance system, and trends in drug pricing based on these regulations and systems. However, the products under development are expected to require a considerable period before they can actually be launched, and there is no guarantee that these regulations, systems or pricing trends will remain unchanged during that period.」
Continues to indicate the risks of changes in pharmaceutical regulations, the healthcare insurance system and drug prices. - FY2017RestatedAnnual report
「The company's business plan is based on existing legal regulations, including the Pharmaceutical Affairs Law, the healthcare insurance system, and trends in drug pricing based on these regulations and systems. However, the products under development are expected to require a considerable period before they can actually be launched, and there is no guarantee that these regulations, systems or pricing trends will remain unchanged during that period.」
Continues to indicate the risks of changes in pharmaceutical regulations, the healthcare insurance system and drug prices. - FY2016First statedAnnual report
「The company's business plan is based on existing legal regulations, including the Pharmaceutical Affairs Law, the healthcare insurance system, and trends in drug pricing based on these regulations and systems. However, the products under development are expected to require a considerable period before they can actually be launched, and there is no guarantee that these regulations, systems or pricing trends will remain unchanged during that period.」
Indicates that regulations, the healthcare insurance system and pricing may change during the lengthy development period.